|Numéro de publication||US20080167620 A1|
|Type de publication||Demande|
|Numéro de demande||US 11/651,425|
|Date de publication||10 juil. 2008|
|Date de dépôt||9 janv. 2007|
|Date de priorité||9 janv. 2007|
|Autre référence de publication||US7713258, US20090048578, WO2008086007A1|
|Numéro de publication||11651425, 651425, US 2008/0167620 A1, US 2008/167620 A1, US 20080167620 A1, US 20080167620A1, US 2008167620 A1, US 2008167620A1, US-A1-20080167620, US-A1-2008167620, US2008/0167620A1, US2008/167620A1, US20080167620 A1, US20080167620A1, US2008167620 A1, US2008167620A1|
|Inventeurs||John M. Adams, Clifton A. Alferness|
|Cessionnaire d'origine||Seattle Medical Technologies|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Référencé par (10), Classifications (8), Événements juridiques (3)|
|Liens externes: USPTO, Cession USPTO, Espacenet|
Tight control over the delivery of insulin in both type I diabetes (usually juvenile onset) and type II diabetes (usually late adult onset), has been shown to improve the quality of life as well as the general health of these patients. Insulin delivery has been dominated by subcutaneous injections of both long acting insulin to cover the basal needs of the patient and by short acting insulin to compensate for meals and snacks. Recently, the development of electronic, external insulin infusion pumps has allowed the continuous infusion of fast acting insulin for the maintenance of the basal needs as well as the compensatory doses (boluses) for meals and snacks. These infusion systems have shown to improve control of blood glucose levels. However, they suffer the drawbacks of size, cost, and complexity. For example, these pumps are electronically controlled and must be programmed to supply the desired amounts of basal and bolus insulin. This prevents many patients from accepting this technology over the standard subcutaneous injections.
Hence, there is a need in the art for a convenient form of insulin treatment which does not require significant programming or technical skills to implement to service both basal and bolus needs. Preferably, such a treatment would be carried out by an infusion device that is simple to use and mechanically driven negating the need for batteries and the like. It would also be preferable if the infusion device could be directly attached to the body and not require any electronics to program the delivery rates. The insulin is preferably delivered through a small, thin-walled tubing (cannula) through the skin into the subcutaneous tissue similar to technologies in the prior art.
While the idea of such a simple insulin delivery device is compelling, many obstacles must be overcome before such a device may become a practical realty. One problem resides in insulin supply. Patients vary greatly on the amount of insulin such a device must carry to provide treatment over a fixed time period of, for example, three days. This is one environment where one size does not fit all.
Another problem is with cannula deployment to support insulin delivery. Cannula deployment to support delivery of the insulin beneath the patient's skin must be made easy and convenient. This is not as easy as it seems because cannula deployment, as generally and currently performed in the art, requires insertion of a cannula-carrying needle into the patient and then retraction of only the needle to leave the cannula in place beneath the patient's skin.
When needles are introduced beneath a patient's skin, during an injection, for example, it is well known that the pain associated with the injection may be reduced by forming a fold in the skin at the injection site prior to the injection. The fold of skin can also increase the probability that only soft tissue will be affected during the injection. However, the forming of such a skin fold when the needle is also being driven through an associated device, such as in infusion device, for example, to deliver a cannula to a deployed position extending from the device to beneath the skin is not readily possible. The reason for this is that in such cases, the device is already adhered to the skin and covers the injection site, making it virtually impossible to form a desired skin fold to receive the needle and cannula. As will be seen subsequently, the present invention addresses these and other issues toward providing a simple, practical, reliable and relatively pain-free deployment of a cannula beneath the skin to support insulin delivery.
The invention provides a medical device comprising a base having a base surface and a flexible layer member. The flexible layer member has a first surface adjacent the base surface and a second surface adapted to be adhered to a patient's skin. The first surface has a first portion adhered to a portion of the base surface and a second portion adherable to the base surface.
The base surface and the flexible layer member may be arranged to permit a cannula to pass there through from the base. The base may be arranged to permit a cannula to pass through the first portion of the first surface. The base may include a septum within the base surface to permit a cannula to pass through the first portion of the first surface.
The second portion of the first surface may include a layer of adhesive and a removable cover overlying the layer of adhesive. The second portion of the first surface may include first and second areas on opposite sides of the first portion. The base surface and the flexible layer member are preferably arranged to permit a cannula to pass there through from the base. The base may be further arranged to permit a cannula to pass through the first portion of the first surface. The base may include a septum within the base surface to permit a cannula to pass there the first portion of the first surface. The first and second areas of the first surface may each include a layer of adhesive and a removable cover overlying the layer of adhesive.
The invention may further provide a method of deploying a cannula of a disposable infusion device. The method comprises the steps of adhering, to a skin surface, a base member having a port for receiving a cannula, forming a skin fold having skin surfaces sloping away from opposite sides of the base member and driving a cannula through the port of the base member while maintaining the skin fold and thereafter releasing the skin fold.
The step of forming the skin fold may include compressing soft tissue beneath and on opposite sides of the base member. The adhering step may include adhering a first portion of the base member to the skin surface before forming the skin fold and adhering an additional portion of the base member to the skin surface after releasing the skin fold. The additional portion of the base member may be a portion of the base member remaining to be adhered to the skin surface.
The method may further include the step of releasably attaching to the base member a cannula driver having a cannula and a drive mechanism for driving the cannula from the cannula driver into and through the port of the base member. The driving step may then include actuating the drive mechanism to drive the cannula into and through the base member port.
The method may include the further step of removing the cannula driver from the base member after the cannula has been driven through the base member port to a deployed position extending from the base member to beneath the skin. The step of forming the skin fold may include compressing soft tissue beneath and on opposite sides of the base member. The adhering step may include the steps of adhering a first portion of the base member to the skin surface before forming the skin fold and adhering an additional portion of the base member to the skin surface after releasing the skin fold. The additional portion of the base member may be a portion of the base member remaining to be adhered to the skin surface.
The features of the present invention which are believed to be novel are set forth with particularity in the appended claims. The invention, together with further features and advantages thereof, may best be understood by making reference to the following description taken in conjunction with the accompanying drawings, in the several figures of which like reference numerals identify identical elements, and wherein:
Referring now to
The base 130 has a base surface 132 and the flexible member 140 includes a first surface 142 adjacent the base surface 132 of the device base 130 and a second surface 144 adapted to be adhered to the skin. The flexible member 140 carries three protective strips 150, 152, and 154. Each strip has a respective tab 150 a, 150 2 , and 154 a to facilitate its removal. The first strip 150, when removed, exposes a layer of adhesive for use in adhering the second surface 144 of the flexible member 140 to the patient's skin. The second and third strips 152 and 154, when removed, expose an adhesive on the first surface 142 of the flexible member to the base surface 132 of the device. The strips 152 and 154 cover outer regions of the flexible member first surface 142 leaving a center region 146 already adhered to the base surface 132 of the device base 130. As will be seen subsequently, after a cannula has been deployed, the strips 152 and 154 may be removed to expose the adhesive in the outer regions of the first surface 142 of the flexible member 140 to the base surface 132 of the device 130. This permits the entire base surface 132 to be adhered to the flexible member 140 to more fully stabilize the device 100 on the patient's skin after cannula deployment.
The device 100 further includes a pair of actuator buttons of which one such button 112 may be seen in
The cannula driver 200 is arranged to be detachably received on the infusion device 100 to facilitate deployment of a cannula from the device 100. To that end, the driver 200 includes a plurality of projections 202 that are arranged to align with and be frictionally received by a like plurality of recesses 114 within the body 120 of the infusion device 100. The projections 202 and the recesses 114 are correspondingly arranged to serve the further function of aligning the cannula driver 200 with the infusion device 100 for cannula deployment. The cannula driver 200 still further includes an actuator button 220. When the actuator button 220 is depressed, a mechanism (not shown) within the cannula driver is released to first drive a cannula carried on a cannula needle through the device 100 to a deployed position and then retract the needle back into the cannula driver 200 leaving the cannula deployed and ready to provide insulin to the patient. For a complete description of an exemplary cannula driver, reference may be had to copending application Ser. No. 11/641,596, filed Dec. 18, 2006 for CANNULA DELIVERY APPARATUS AND METHOD FOR A DISPOSABLE INFUSION DEVICE, which application is assigned to the assignee of the present invention and incorporated in its entirety herein by reference.
The assembly 170 is seen with the cannula 174 being carried by a needle 172. Once the assembly is positioned as shown, the needle 172 is withdrawn from the cannula 174 and preferably transported back to the cannula driver 200 for safe sharps disposal.
With the cannula 174 deployed and the needle 172 withdrawn back into the cannula driver 200 as shown in
While particular embodiments of the present invention have been shown and described, modifications may be made, and it is therefore intended in the appended claims to cover all such changes and modifications which fall within the true spirit and scope of the invention as defined by those claims.
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|US7828771||28 juil. 2008||9 nov. 2010||Entra Pharmaceuticals, Inc.||Systems and methods for delivering drugs|
|US7872396||26 juil. 2007||18 janv. 2011||Massachusetts Institute Of Technology||Electrochemical actuator|
|US7923895||10 sept. 2008||12 avr. 2011||Massachusetts Institute Of Technology||Electrochemical methods, devices, and structures|
|US7994686||26 avr. 2007||9 août 2011||Massachusetts Institute Of Technology||Electrochemical methods, devices, and structures|
|US7999435||21 févr. 2008||16 août 2011||Massachusetts Institute Of Technology||Electrochemical actuator|
|US8093781||3 déc. 2010||10 janv. 2012||Massachusetts Institute Of Technology||Electrochemical actuator|
|US8226606 *||28 sept. 2007||24 juil. 2012||Calibra Medical, Inc.||Disposable infusion device with tactile dosage volume indicator|
|US8246578 *||22 déc. 2008||21 août 2012||Terumo Kabushiki Kaisha||Puncture device|
|US20090088692 *||28 sept. 2007||2 avr. 2009||Seattle Medical Technologies, Inc.||Disposable infusion device with tactile dosage volume indicator|
|US20110015659 *||22 déc. 2008||20 janv. 2011||Terumo Kabushiki Kaisha||Puncture device|
|Classification aux États-Unis||604/180|
|Classification coopérative||A61M2005/1585, A61M2005/1405, A61M5/425, A61M5/14248|
|Classification européenne||A61M5/42C, A61M5/142P2|
|15 juin 2007||AS||Assignment|
Owner name: SEATTLE MEDICAL TECHNOLOGIES, WASHINGTON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ADAMS, JOHN M.;ALFERNESS, CLIFTON A.;REEL/FRAME:019446/0048;SIGNING DATES FROM 20070219 TO 20070226
|8 juil. 2008||AS||Assignment|
Owner name: CALIBRA MEDICAL, INC.,CALIFORNIA
Free format text: CHANGE OF NAME;ASSIGNOR:SEATTLE MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:021204/0708
Effective date: 20080616
|26 juin 2012||AS||Assignment|
Owner name: CALIBRA MEDICAL, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALFERNESS, CLIFTON A.;ADAMS, JOHN;REEL/FRAME:028446/0460
Effective date: 20120619